Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: Clusterin expression as a novel prognostic factor

Journal of Dermatological Science

Volumn 71, Issue 3, 2013, Pages 160-166

  Tobisawa, Shini ichi ^a   Honma, Masaru ^a   Ishida Yamamoto, Akemi ^a   Saijo, Yasuaki ^a   Iizuka, Hajime ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Clusterin; Cutaneous T cell lymphoma; Mycosis fungoides; Prognosis; S zary syndrome

Indexed keywords

CD30 ANTIGEN; CLUSTERIN; KI 67 ANTIGEN; LACTATE DEHYDROGENASE;

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERNATIONAL SOCIETY FOR CUTANEOUS LYMPHOMAS REVISED STAGING SYSTEM; JAPANESE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PERFORMANCE STATUS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEZARY SYNDROME; TASK PERFORMANCE;

CLUSTERIN; CUTANEOUS T-CELL LYMPHOMA; MYCOSIS FUNGOIDES; PROGNOSIS; SÉZARY SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; ASIAN CONTINENTAL ANCESTRY GROUP; CLUSTERIN; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOSIS FUNGOIDES; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SEZARY SYNDROME; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84881555639     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.04.020     Document Type: Article

References (66)

1. Lutzner M., Edelson R., Schein P., Green I., Kirkpatrick C., Ahmed A. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 1975, 83:534-552.
2. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
3. Green S.B., Byar D.P., Lamberg S.I. Prognostic variables in mycosis fungoides. Cancer 1981, 47:2671-2677.
4. Lamberg S.I., Green S.B., Byar D.P., Block J.B., Clendenning W.E., Douglas M.C., et al. Clinical staging for cutaneous T-cell lymphoma. Ann Intern Med 1984, 100:187-192.
5. Sausville E.A., Worsham G.F., Matthews M.J., Makuch R.W., Fischmann A.B., Schechter G.P., et al. Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 1985, 16:1098-1109.
6. Schechter G.P., Sausville E.A., Fischmann A.B., Soehnlen F., Eddy J., Matthews M., et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood 1987, 69:841-849.
7. Sausville E.A., Eddy J.L., Makuch R.W., Fischmann A.B., Schechter G.P., Matthews M., et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988, 109:372-382.
8. Merlo C.J., Hoppe R.T., Abel E., Cox R.S. Extracutaneous mycosis fungoides. Cancer 1987, 60:397-402.
9. Marti R.M., Estrach T., Reverter J.C., Mascaro J.M. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991, 127:1511-1516.
10. Kim Y.H., Bishop K., Varghese A., Hoppe R.T. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995, 131:1003-1008.
11. Kim Y.H., Liu H.L., Mraz-Gernhard S., Varghese A., Hoppe R.T. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003, 139:857-866.
12. Hoppe R.T., Medeiros L.J., Warnke R.A., Wood G.S. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995, 32:448-453.
13. Wasik M.A., Vonderheid E.C., Bigler R.D., Marti R., Lessin S.R., Polansky M., et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma: clinical and prognostic implications. Arch Dermatol 1996, 132:42-47.
14. Toro J.R., Stoll H.L., Stomper P.C., Oseroff A.R. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 1997, 37:58-67.
15. Vonderheid E.C., Ekbote S.K., Kerrigan K., Kalmanson J.D., Van Scott E.J., Rook A.H., et al. The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma. J Invest Dermatol 1998, 110:946-950.
16. Vonderheid E.C., Pena J., Nowell P. Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging. Leuk Lymphoma 2006, 47:1841-1856.
17. Diamandidou E., Colome M., Fayad L., Duvic M., Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 1999, 40:914-924.
18. Zackheim H.S., Amin S., Kashani-Sabet M., McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999, 40:418-425.
19. Weinstock M.A., Reynes J.F. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer 1999, 85:208-212.
20. van Doorn R., Van Haselen C.W., van Voorst Vader P.C., Geerts M.L., Heule F., de Rie M., et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000, 136:504-510.
21. Vergier B., de Muret A., Beylot-Barry M., Vaillant L., Ekouevi D., Chene G., et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000, 95:2212-2218.
22. Fraser-Andrews E.A., Woolford A.J., Russell-Jones R., Seed P.T., Whittaker S.J. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 2000, 114:117-121.
23. Fraser-Andrews E.A., Mitchell T., Ferreira S., Seed P.T., Russell-Jones R., Calonje E., et al. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. Br J Dermatol 2006, 155:756-762.
24. Scarisbrick J.J., Whittaker S., Evans A.V., Fraser-Andrews E.A., Child F.J., Dean A., et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001, 97:624-630.
25. Foulc P., N'Guyen J.M., Dreno B. Prognostic factors in Sézary syndrome: a study of 28 patients. Br J Dermatol 2003, 149:1152-1158.
26. Klemke C.D., Mansmann U., Poenitz N., Dippel E., Goerdt S. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol 2005, 153:118-124.
27. Juarez T., Isenhath S.N., Polissar N.L., Sabath D.E., Wood B., Hanke D., et al. Analysis of T-cell receptor gene rearrangement for predicting clinical outcome in patients with cutaneous T-cell lymphoma: a comparison of Southern blot and polymerase chain reaction methods. Arch Dermatol 2005, 141:1107-1113.
28. Abeni D., Frontani M., Sampogna F., Sera F., Bolli S., Corona R., et al. Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol 2005, 153:324-330.
29. Morales M.M., Putcha V., Evans H.S., Olsen J., Llopis A., Moller H. Survival of mycosis fungoides in patients in the Southeast of England. Dermatology 2005, 211:325-329.
30. Vidulich K.A., Talpur R., Bassett R.L., Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 2009, 48:243-252.
31. Bunn P.A., Lamberg S.I. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979, 63:725-728.
32. Suzuki S., Ito K., Ito M., Kawai K. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome. J Dermatol Sci 2010, 57:37-43.
33. Agar N.S., Wedgeworth E., Crichton S., Mitchell T.J., Cox M., Ferreira S., et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010, 28:4730-4739.
34. Quaglino P., Pimpinelli N., Berti E., Calzavara-Pinton P., Alfonso Lombardo G., Rupoli S., et al. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 2012, 118:5830-5839.
35. Talpur R., Singh L., Daulat S., Liu P., Seyfer S., Trynosky T., et al. Long-term outcomes of 1263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 2012, 18:5051-5060.
36. Olsen E., Vonderheid E., Pimpinelli N., Willemze R., Kim Y., Knobler R., et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110:1713-1722.
37. Olsen E.A., Whittaker S., Kim Y.H., Duvic M., Prince H.M., Lessin S.R., et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011, 29:2598-2607.
38. Arulogun S.O., Prince H.M., Ng J., Lade S., Ryan G.F., Blewitt O., et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 2008, 112:3082-3087.
39. Barberio E., Thomas L., Skowron F., Balme B., Dalle S. Transformed mycosis fungoides: clinicopathological features and outcome. Br J Dermatol 2007, 157:284-289.
40. Diamandidou E., Colome-Grimmer M., Fayad L., Duvic M., Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998, 92:1150-1159.
41. Greer J.P., Salhany K.E., Cousar J.B., Fields J.P., King L.E., Graber S.E., et al. Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process. Hematol Oncol 1990, 8:215-227.
42. Salhany K.E., Cousar J.B., Greer J.P., Casey T.T., Fields J.P., Collins R.D. Transformation of cutaneous T cell lymphoma to large cell lymphoma: a clinicopathologic and immunologic study. Am J Pathol 1988, 132:265-277.
43. Petit B., Chaury M.P., Le Clorennec C., Jaccard A., Gachard N., Moalic-Judge S., et al. Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica 2005, 90:200-206.
44. Gambichler T., Bischoff S., Bechara F.G., Altmeyer P., Kreuter A. Expression of proliferation markers and cell cycle regulators in T cell lymphoproliferative skin disorders. J Dermatol Sci 2008, 49:125-132.
45. Purrello M., Bettuzzi S., Di Pietro C. The gene for SP-40, 40, human homolog of rat sulfated glycoprotein 2, rat clusterin, and rat testosterone-repressed prostate message 2, maps to chromosome 8. Genomics 1991, 10:151-156.
46. Tobe T., Minoshima S., Yamase S., Choi N.H., Tomita M., Shimizu N. Assignment of a human serum glycoprotein SP-40,40 gene (CLI) to chromosome 8. Cytogenet Cell Genet 1991, 57:193-195.
47. Wellmann A., Thieblemont C., Pittaluga S., Sakai A., Jaffe E.S., Siebert P., et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 2000, 96:398-404.
48. Saffer H., Wahed A., Rassidakis G.Z., Medeiros L.J. Clusterin expression in malignant lymphomas: a survey of 266 cases. Mod Pathol 2002, 15:1221-1226.
49. Lae M.E., Ahmed I., Macon W.R. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol 2002, 118:773-779.
50. Nascimento A.F., Pinkus J.L., Pinkus G.S., Clusterin a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms. Am J Clin Pathol 2004, 121:709-717.
51. Olsen S.H., Ma L., Schnitzer B., Fullen D.R. Clusterin expression in cutaneous CD30-positive lymphoproliferative disorders and their histologic stimulants. J Cutan Pathol 2009, 36:302-307.
52. Pimpinelli N., Olsen E.A., Santucci M., Vonderheid E., Haeffner A.C., Stevens S., et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005, 53:1053-1063.
53. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
54. Vonderheid E.C., Bernengo M.G., Burg G., Duvic M., Heald P., Laroche L., et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002, 46:95-106.
55. Sun G., Berthelot C., Li Y., Glass D.A., George D., Pandya A., et al. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol 2009, 60:231-235.
56. Schmid M.H., Bird P., Dummer R., Kempf W., Burg G. Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept. Arch Dermatol 1999, 135:1204-1208.
57. Kim Y.H., Chow S., Varghese A., Hoppe R.T. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999, 135:26-32.
58. Marti R.M., Pujol R.M., Servitje O., Palou J., Romagosa V., Bordes R., et al. Sézary syndrome and related variants of classic cutaneous T-cell lymphoma: a descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma 2003, 44:59-69.
59. Bernengo M.G., Quaglino P., Novelli M., Cappello N., Doveil G.C., Lisa F., et al. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol 1998, 9:857-863.
60. Kim Y.H., Jensen R.A., Watanabe G.L., Varghese A., Hoppe R.T. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol 1996, 132:1309-1313.
61. de Coninck E.C., Kim Y.H., Varghese A., Hoppe R.T. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001, 19:779-784.
62. Benner M.F., Jansen P.M., Vermeer M.H., Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 2012, 119:1643-1649.
63. Edinger J.T., Clark B.Z., Pucevich B.E., Geskin L.J., Swerdlow S.H. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 2009, 33:1860-1868.
64. Heenen M., Thiriar S., Noel J.C., Galand P. Ki-67 immunostaining of normal human epidermis: comparison with 3H-thymidine labelling and PCNA immunostaining. Dermatology 1998, 197:123-126.
65. Humphreys D.T., Carver J.A., Easterbrook-Smith S.B., Wilson M.R. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999, 274:6875-6881.
66. Viard I., Wehrli P., Jornot L., Bullani R., Vechietti J.L., Schifferli J.A., et al. Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J Invest Dermatol 1999, 112:290-296.